Current Headlines

1. PerturbAI And OpenAI Unveil First-Of-Its-Kind AI Reasoning Agents To Scale Biomedical Discovery 10/21/2026

   PerturbAI, an AI-native biotechnology company, today announced results from its year-long collaboration with OpenAI to advance biomedical research and drug discovery.

2. Healthcare And Life Sciences Leaders Build On NVIDIA To Advance Drug Discovery And Expand Patient Care 10/21/2026

   NVIDIA today announced collaborations with leading global healthcare and research organizations to advance protein design — including through a newly released open model, RFD4-Proteina — accelerate drug discovery and bring greater precision to cancer care.

3. Samsung Bioepis Receives FDA Fast Track Designation For SBE303, Company's First Antibody-Drug Conjugate (ADC) Candidate 10/21/2026

   Samsung Bioepis Co., Ltd. today announced that the company’s antibody-drug conjugate (ADC) candidate, SBE303, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA).

4. Cosette Pharmaceuticals Announces FDA Approval Of EVOXAC (cevimeline HCl) Oral Solution, Marking Cosette's First New Drug Application (NDA) Approval 10/20/2026

   Cosette Pharmaceuticals, Inc. (“Cosette”), a U.S.-based specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved EVOXAC (cevimeline HCl) oral solution for the treatment of symptoms of dry mouth in adults with Sjögren’s disease.

5. Sinopia Biosciences Secures $2.5M NIH Grant To Advance Metabolomics Foundation Model For Drug Discovery 10/20/2026

   Sinopia Biosciences, Inc., a biotechnology company leveraging multi-omics data, high-throughput screening, and artificial intelligence to identify and develop first-in-class therapies for diseases with significant unmet need, today announced it has been awarded a $2.5M Small Business Innovation Research (SBIR) Phase II grant (R44GM154585) from the National Institute of General Medical Sciences (NIGMS), part of the National Institutes of Health (NIH).

6. Insilico Medicine And Servier Achieve First Milestone In AI-Driven R&D Collaboration, Triggering An Undisclosed Milestone Payment 10/20/2026

   Insilico Medicine ("Insilico", HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced that the company has achieved the early drug discovery milestone in its multi-year AI-driven drug discovery collaboration with Servier, an independent international pharmaceutical group governed by a foundation.

7. Vistagen Selects GATC Health To Apply Predictive AI Across Lead Clinical-Stage Drug Development Programs 10/20/2026

   Vistagen (Nasdaq: VTGN) a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry, today announced its collaboration with GATC Health, a tech-bio company applying artificial intelligence and multiomics to drug discovery and development.

8. United Therapeutics Announces FDA Clearance To Proceed With SUMMIT Clinical Trial For Treprostinil SMI In PH-COPD 10/19/2026

   United Therapeutics Corporation, a public benefit corporation, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance under the company’s investigational new drug application to proceed with the SUMMIT clinical trial of treprostinil SMI in PH-COPD.

9. UroGen Announces FDA Acceptance Of The New Drug Application For UGN-103, An Investigational Treatment For Adults With Recurrent LG-IR-NMIBC 10/19/2026

   UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced U.S. Food and Drug Administration (FDA) acceptance of the New Drug Application (NDA) for investigational drug UGN-103 (mitomycin) for intravesical solution for the treatment of adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).

10. Element Biosciences Launches Cytos, Scaling Multiomics To Labs Of Every Size 10/19/2026

    Element Biosciences, Inc. today announced the first shipment of Cytos, a first-of-its-kind multiomics workflow that captures guide RNA, cell morphology, protein expression, and whole transcriptome from the very same single cell in a single run.